Evidence map›Paper›PMID 39820757›Full record

ArticleScientific reports2025

Custom exome panel revealed new mutations in MAPK14 and novel mutation in RUNX2 gene in patients with PCOS.

Yunus Arikan, Taylan Onat

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Living with PCOS: A Narrative of its Biology, Diagnosis, and Evolving Treatment.Endocrine, metabolic & immune disorders drug targets · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yunus ArikanFaculty of Medicine, Department of Medical Genetics, Yozgat Bozok University, Yozgat, Turkey. yunus.arikan@yobu.edu.tr.
Taylan OnatFaculty of Medicine, Department of Obstetrics and Gynaecology, Inonü University, Malatya, Turkey.

Funding

Yozgat Bozok University, Scientific Research and Projects Coordination Units 6602c-TF/21-469
6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy and is both phenotypically and genotypically heterogeneous. A large number of genetic variants have been found in different genes, so far. Based on the literature, we identified 7 genes and aimed to find new causative variants in these genes. We created a targeted PCOS panel including major genes in the steroidogenezis, WNT, MAPK, and TGFβ pathways and analyzed whole-exome sequencing results. We compared the minor allele frequency (MAF) values of different variants with our results and calculated deleterious scores of newly found variants using various web-based prediction tools and ACMG pathogenicity criteria. We found a novel missense mutation (p.Thr355Ile) in the RUNX2 gene in one patient and heterozygous mutations in the MAPK14 gene (c.306_5delT and c.*8G > T) in another patient with PCOS. Five novel pathogenic moderate (PM2) intronic variants in 4 different genes in total were introduced for the first time. We also decoded 7 genes in patients with PCOS in our cohort. Two more candidate genes (MAPK14 and RUNX2) may be related to PCOS.

Indexed as

Core Binding Factor Alpha 1 SubunitExomeMutationPolycystic Ovary SyndromeAdultExome SequencingFemaleGene FrequencyGenetic Predisposition to DiseaseHumansMutation, MissenseCore Binding Factor Alpha 1 SubunitRUNX2 protein, humanMAPK14PCOSRUNX2Targeted exome panel

Identifiers

PMID39820757
PMCPMC11739400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.